Zanoprima Appoints New CEO
Zanoprima Life Sciences announces the appointment of Anand Ashok as Chief Executive Officer, effective March 2025. Son of founding member Ashok Narasimhan, Anand joined the company’s Board of Directors on January 15, 2025. Based in London, he will now lead Zanoprima’s global business operations and strategic growth initiatives.
Zanoprima Showcases Synic™ Benefits at Next Generation Nicotine Conference 2025
Zanoprima was proud to be a sponsor of the 7th Annual Next Generation Nicotine conference held at Miami in June 2025. We really enjoyed some insightful and fruitful discussions with several colleagues from the industry. In a Spotlight session, Eric Johnson from Atlantic Consulting presented the results from the recent environmental study showing the benefits of our patented synthetic nicotine (Synic™) against tobacco-derived nicotine.
Anand Ashok (CEO) and Bill Jackson (Director of Development & Manufacturing) were both in attendance.
Saving 100 Million Lives by 2060
Global health expert Dr. Derek Yach reaffirmed the scientific basis of Tobacco Harm Reduction (THR) in his recent article. His insights reinforce the importance of THR as a proven public health strategy — aligning closely with Zanoprima’s core objective of saving lives through innovative, science-backed harm reduction solutions.